부산대학교 도서관

Girolamo Ranieri,1 Artor Niccoli Asabella,2 Corinna Altini,2 Vito Fazio,1 Luciana Caporusso,1 Ilaria Marech,1 Gianluca Vinciarelli,1 Francesco Macina,1 Dario de Ceglia,1 Margherita Fanelli,2 Michele Ammendola,3,4 Giuseppe Rubini,2 Cosmo Damiano Gadaleta1 1Diagnostic and Interventional Radiology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, 2Nuclear Medicine Unit, University of Bari “Aldo Moro”, Bari, 3Department of Medical and Surgery Science, Clinical Surgery Unit, “Magna Graecia” Medical School, Catanzaro, 4Surgery Unit, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II”, Bari, Italy Background: The main aim of this prospective study was to evaluate the efficacy of drug-eluting beads with irinotecan (DEBIRI) for liver metastases from colorectal cancer. Secondary aims were to evaluate survival and toxicity. Methods: Twenty-five patients with metastases in 0.05). The median OS was 37 months (95% CI: 13.881 to 60.119). Cox regression model showed that neither site, Dukes’ classification, grading, Kras status nor number of chemotherapy treatments pre-DEBIRI influenced the OS. The log-rank test showed no statistically significant difference in OS among patients who underwent 1, 2 or 3 DEBIRI treatments (χ2=2.831, P=0.09). In our study, the main toxicities included postembolization syndrome (PES), hypertransaminasemia and fever. Conclusion: The favorable tumor response and the favorable toxicity profile make DEBIRI treatment a potential third-line therapy. Although further larger studies are needed to confirm these data, we can state that DEBIRI is an attractive emerging treatment in these patients. Keywords: colorectal cancer, liver metastases, transarterial chemoembolization, DEBIRI